Johnson & Johnson has been facing turbulent times with both positive and negative aspects influencing the stock. Earnings estimates for the company have been decreased by Zacks Research, while GUNN & Co Investment Management has chosen to increase its stake in the company. Johnson & Johnson's quarterly profit ended up exceeding estimates primarily because of a jump in medical device sales. The company recently agreed to a $6.5 billion deal to settle a long-standing talcum baby powder lawsuit. However, another lawsuit cost them $45 million in damages. Despite market fluctuations, Johnson & Johnson's stock appears to be keeping investors' interest. They have introduced a dividend increase to $1.24 and are in talks for making a deal with Shockwave Medical. Johnson & Johnson has made strides in innovation and recently spilled onto Fortune's list of most innovative companies. However, their plans for lay-offs as services with another firm conclude have shown a mixed picture of the firm's overall situation. Considering Johnson & Johnson's focus on AI, sustainability, global health equity and diversity along with the steady increase in medical device and pharmaceutical sales, it has been a mixed bag of progress and set-backs.
Johnson Johnson JNJ News Analytics from Thu, 20 Jul 2023 07:00:00 GMT to Sun, 12 May 2024 12:20:00 GMT -
Rating 4
- Innovation 7
- Information 6
- Rumor -3
